An Israeli Lab Built a PTSD Treatment That Never Asks You to Relive It.
PTSD keeps dragging people back to the worst day of their life. The only cure we had made them go there on purpose. An Israeli lab just built one that doesn’t.
A car door slams and the body is already back there. A smell, a date on the calendar, a certain slant of afternoon light, and the whole system floods like the worst moment is happening right now. That is PTSD doing its work. The danger ended years ago, but nobody told the alarm, and it keeps firing. The person isn’t remembering the fear. Their body is reliving it, dragged all the way back as if it were happening now.
And the cruelty runs deeper. For as long as we’ve had a name for this, the best treatment we built asked the sufferer to do the one thing the condition makes unbearable: go back. The leading therapy works by taking you back into it, out loud, to a stranger, again and again, until it supposedly loses its grip. For the people who can do it, it works. But going back is the exact thing PTSD has spent years making unendurable, so many never start, and many who start walk out. The cure was the thing they couldn’t face twice.
Then a lab in Israel built one that doesn’t ask. The company that turned it into a real treatment is called GrayMatters Health, and to see what they actually did, you have to start with the part of the brain nobody could reach.
An Alarm That Forgets to Shut Off
To beat it you have to understand where it lives. Deep inside your brain, roughly level with your temples, sits a small almond-shaped structure called the amygdala. Think of it as a smoke alarm. Its whole job is to spot danger fast and pull the fire handle before the thinking part of your brain has caught up. That’s not a design flaw, it’s a big part of why our species is still here. The trouble starts when it won’t switch off. Something terrible happens, the alarm does exactly what it was built to do, and then the danger passes but the alarm never gets the message, and it runs hot for years.
You Can’t Turn Down What You Can’t See
Medication can turn the volume down, but it doesn’t knock on the amygdala’s door. It floods the whole brain with chemistry just to reach one overheated corner. It manages the alarm. It never teaches you to reach it.
Think about the slow, deliberate breath you take to steady yourself before something hard. Nobody taught you that. You just know that if you breathe slow, the panic loosens its grip, and you can feel it work, because in that moment you are reaching into your own nervous system and turning a dial. That is the thing no trauma treatment could ever offer for the amygdala itself: a way to reach in and turn it down on purpose. And the reason is almost stupidly simple. You cannot turn down a thing you cannot see, and you cannot see the amygdala without an fMRI, one of those enormous MRI machines that watches deep-brain activity in real time. Those are expensive, cumbersome, and impractical for routine clinical practice. You don’t put one in a clinic, let alone send one home with a patient. The cheap, portable option, an EEG cap, only reads the surface of the brain, and the amygdala sits too deep for it. So the one structure you’d most want to show a patient was the one the affordable machine couldn’t find.
For years that’s where it sat. A problem everyone in the field could state in a sentence and nobody could get around, until an Israeli lab decided the sentence wasn’t a wall. It was a dare.
So They Tried the Thing You’re Not Supposed to Be Able to Do
Professor Talma Hendler runs the Sagol Brain Institute at Tel Aviv Sourasky Medical Center and teaches neuroscience and psychiatry at Tel Aviv University. Her team was the first in Israel to record EEG and fMRI at the same time in a living person, and the first anywhere to show, in a real prospective study, that the amygdala is a marker for who breaks under traumatic stress and who doesn’t. So when she and her team looked at that wall, they had earned the right to ask something ridiculous.
What if you could teach the cheap cap to see what only the expensive machine can see?
The amygdala is too far down for the cap to hear directly. But when it fires, the ripple has to travel out through the rest of the brain to reach the surface, and somewhere in the noise the cap already picks up, it might leave a faint signature on the way. Nobody had ever pulled that signature out of the static. Maybe it could be done.
So they did the thing the long way. They slid a person into the fMRI, the tube that can see the deep spot light up, and at the same instant they read that same person’s brain from the surface with the cap. Tube and cap, the same brain, the same moment. Then another person. Then another, and another, building a stack of matched pairs: here is what the deep spot was doing, and here is the faint smudge it left on the surface at that exact second. Stare at enough of those pairs and the smudge stops being random. It becomes a face you can recognize. Show the cap a fresh surface reading now, with no tube anywhere in the room, and it can tell you what the deep spot is doing.
They called it the Electrical fingerprint of the amygdala, and they published it under exactly that title in Nature Human Behaviour in 2019. It made GrayMatters the first company to build a brain-region-specific biomarker for mental health, a way to watch one deep structure and let a patient learn to steer it themselves.
And it worked.
An ordinary, portable cap could now watch a part of the brain that had always demanded a machine the size of a room. The one door into the amygdala that money and physics had kept shut was open, and it opened from the cheap side.
And they still weren’t done, because a paper in a journal is not something a clinic can use on a Tuesday morning. In 2018 the company got founded in Haifa by Oded Kraft, Rani Cohen and Shai Attia to turn the science into something a clinic could actually use, which meant five more years of engineering, multinational trials, and a regulatory file thick enough to stop a door. The FDA cleared it in March 2023. Fourteen years from soldiers in a scanner to a device with a label on it.
Nobody Asks You What Happened
Prism is what came out of all that. You sit down in a clinic, you put on the cap, and for the first time the alarm that has been running your life is something you can see on a screen in front of you.
The experience is non-trauma-based. Nobody asks what happened. You don’t describe the worst day. You don’t go back. In the company’s own careful phrasing, the headset and simulation create an environment where patients engage in a non-trauma-based experience to learn to control their PTSD symptoms.
This is the door the old treatments couldn’t open. Nobody asks you to go back into the vehicle, the building, the worst few minutes. You put on the cap and you practice, and the memory you’ve spent years refusing to reopen stays closed the whole time.
For decades the only road to relief ran back through the worst day of a person’s life, which is exactly why so many never walked it. This one doesn’t. That is not a small feature on a spec sheet. For the person who could never face going back, it is the whole difference between a treatment that exists and a treatment they can actually use.
What you do instead is play. On the screen in front of you there are animated characters, and they’re agitated, loud, worked up. Your job is to get them to sit down and lower their voices. You can’t do it with a button, because there is no button. You do it from the inside, by finding some thought or memory or feeling of your own that settles you, and when it works you see it work, right there, the characters easing down in real time. What you are actually watching is your own amygdala going quiet. You’re learning, by trial and instant feedback, the same move you already make with a deep breath, except now you can see the alarm itself respond. It runs for about 15 sessions over 6 to 8 weeks in a clinic, with a few boosters if your provider wants them. The strategy that works on screen is the one you carry back out into daily life.
PTSD takes a lot of things from a person. The first one it takes is the feeling of being in charge of your own body and mind. And here the patient is the one running the treatment.
One Soldier Is the Easy Part
Now multiply that one chair by a war. Israel has written combat trauma into its own law, which means the state now has to treat the soldiers who carry it, and that promise runs headfirst into the wall every trauma system hits: you cannot treat a nation’s worth of wounded one therapist at a time. There aren’t enough of them, and there’s no fast way to make more. Since the war began, tens of thousands of soldiers and reservists have entered the rehabilitation system, a great many of them carrying injuries that don’t show up on any scan.
This part is my read, not a claim on the label. GrayMatters built Prism to drop into any psychiatry clinic, and in the company’s own words it can be run by a non-MD, a nurse or a trained operator, with the company installing it and training the staff. You can teach someone to run a station like this. You cannot magic up a psychiatrist who isn’t there. It doesn’t replace the clinician who directs the care, but it changes the question. The old one, where do we find the next trained human, never had a good answer. The new one, where do we set up the next room, actually does.
Where Do You Think the Data Came From?
Return for a moment to that grinding work of teaching the cap to read the amygdala. The tube, the cap, the same brain, the same instant, thousands of times over. All those hours of matched recordings had to come from somewhere. From someone. Whose brains were they reading?
IDF soldiers, scanned before and after combat, in 2009.
The alarm was first mapped in the brains of Israel’s own soldiers, years before any of this had a name or a company or a clearance. They carried the wound in, and by letting a machine read what it did to them, they made the fix possible for everyone who came after. And then the work grew up and left home, into a Nature journal, an FDA file, clinics across the United States.
And then it came back.
There’s a room at Beit Halochem, the network of centers Israel built for its wounded veterans, where the men and women who carried this war walk in twice a week, sit down, and put on the cap. Not to talk about it. Not to go back. Just to get the characters on the screen to sit down and lower their voices, and to carry that quiet back out the door with them. The wound their own generation let a machine study, 17 years ago, is the wound this machine now helps them close. The science left home, grew up, and came back for the people it started with. Of everything in this story, that is the part I love most.
Now the Part I'd Get in Trouble for Skipping
Pride that skips the fine print isn’t worth much.
Prism is cleared by the FDA as an adjunct. The cleared indication describes a neurofeedback software device for relaxation and stress reduction through EEG biofeedback, indicated as an adjunctive treatment of symptoms associated with PTSD, used under the direction of a healthcare professional alongside other interventions. Adjunct is the word that matters. It works alongside therapy and, where a doctor prescribes it, medication, rather than standing in for either. There’s no home version and no app. This is clinical treatment you do with professionals, and in Israel it also carries approval from the Health Ministry’s device division, AMAR.
The evidence is real, peer-reviewed, and has limits worth naming. The pivotal trial met its primary endpoint: about 67% of participants showed clinically significant improvement on the standard scale clinicians use. Clinically significant is the careful phrase for a change big enough to show up in how a person actually lives, not a nudge you’d need a chart to spot. The trial also reported better sleep and a low dropout rate. The side effects people did report, some fatigue, some headache, cleared up on their own. It ran in Psychiatry Research in 2024, with the veteran PTSD researcher Charles Marmar as senior author, and it followed men, women and treatment-resistant combat veterans through the full course.
The limit, said as plainly as the result. It was single-arm and open-label. Nobody got a sham version to compare against, so some of the benefit could come from effects a controlled trial is built to rule out. The investigators said so themselves and called for more investigation, and that work is now underway: a sham-controlled trial comparing Prism against a dummy version is currently enrolling, which is the study that will actually settle the question. A genuine published encouraging result with an honest road still ahead of it, and neither half of that cancels the other.
And the other half of that 67%, because somebody reading this is going to need it said. Roughly a third of the people in that trial did not get a clinically significant response. If you try this and you land in that third, that’s not a verdict on you. It means this particular tool didn’t fit, the way tools sometimes don’t. There are others, and there will be more.
So if you’re carrying this, or somebody you love is, talk to a doctor who can tell you whether this belongs in your care. A Substack, respectfully, is not where that gets decided.
But I wanted you to know it exists. That between a soldier in a scanner in 2009 and a chair at Beit Halochem this week, a handful of Israelis stayed on a problem everyone else had written off, and came out the other side holding a key they could hand to somebody else.
Labs in a dozen richer countries had the same fMRI machines, the same EEG caps, the same 20 years to try. It got done in Israel. We have a habit of reaching the thing everyone else filed under unreachable, and we did it again here.
Built in Israel. For everyone.
This piece is journalism, not medical advice. Nothing here is a diagnosis, a treatment recommendation, or a substitute for professional care. Prism is cleared by the FDA as an adjunctive treatment for PTSD symptoms, to be used under the direction of a healthcare professional. It is not a standalone cure, an at-home device, or a replacement for therapy or medication. If you’re struggling with PTSD or any mental health condition, talk to a qualified clinician about what’s right for you. If you’re in crisis, in the US you can call or text 988; in Israel, ERAN is reachable at 1201.